Astrana Health (NASDAQ:ASTH) Raised to Buy at Wall Street Zen

Astrana Health (NASDAQ:ASTH - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday.

Other analysts also recently issued research reports about the stock. Barclays lifted their target price on shares of Astrana Health from $50.00 to $53.00 and gave the company an "overweight" rating in a report on Friday. BTIG Research raised their price target on Astrana Health from $50.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, July 14th. Truist Financial raised their price target on Astrana Health from $38.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, May 14th. Robert W. Baird set a $45.00 price objective on Astrana Health in a report on Friday, May 8th. Finally, Weiss Ratings raised Astrana Health from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 1st. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $48.29.

Astrana Health Trading Up 4.8%

Shares of ASTH stock opened at $35.76 on Friday. Astrana Health has a 1-year low of $18.08 and a 1-year high of $51.60. The firm has a market cap of $1.99 billion, a PE ratio of 43.61 and a beta of 0.87. The company has a 50-day moving average of $41.36 and a two-hundred day moving average of $32.47. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.35 and a quick ratio of 1.35.

Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.45. Astrana Health had a net margin of 1.05% and a return on equity of 10.43%. The business had revenue of $965.10 million for the quarter, compared to the consensus estimate of $949.21 million. During the same period in the previous year, the firm earned $0.42 EPS. The business's revenue was up 55.6% on a year-over-year basis. On average, analysts predict that Astrana Health will post 1.18 EPS for the current year.

Institutional Investors Weigh In On Astrana Health

Hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC boosted its position in Astrana Health by 57.9% in the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company's stock valued at $26,000 after buying an additional 388 shares during the period. Strs Ohio purchased a new stake in shares of Astrana Health during the fourth quarter worth $40,000. Tower Research Capital LLC TRC increased its position in shares of Astrana Health by 323.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company's stock worth $115,000 after acquiring an additional 3,517 shares during the period. State of Wyoming acquired a new stake in shares of Astrana Health in the second quarter valued at $132,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Astrana Health in the fourth quarter valued at $228,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Astrana Health

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Astrana Health reported non-GAAP earnings of $0.40 per share, up from $0.19 a year earlier and above the $0.31 consensus estimate. A separate report cited $0.80 in EPS versus a $0.34 estimate, reflecting differences between reported and adjusted measures. ASTH Q2 Earnings Top Estimates
• Positive Sentiment: Revenue continued to grow rapidly. Second-quarter revenue reached approximately $972.5 million, an increase of 48.5% year over year. Management and analysts highlighted operating leverage, technology investments and artificial intelligence initiatives as potential drivers of future profitability. ASTH Q2 Deep Dive
• Positive Sentiment: Third-quarter revenue guidance points to continued expansion. Astrana Health forecast revenue of $1.00 billion to $1.03 billion for the third quarter, supporting expectations for sustained growth. ASTH Third-Quarter Revenue Guidance
• Neutral Sentiment: Full-year revenue guidance was maintained at $3.8 billion to $4.1 billion. The midpoint is broadly consistent with the roughly $4.0 billion analyst consensus, suggesting no major change to the outlook. Astrana Health Second-Quarter Results
• Negative Sentiment: Quarterly revenue was below expectations. Revenue of approximately $972.5 million trailed the $985.6 million consensus estimate. Astrana Health also continues to operate with a thin net margin, making execution and cost control important to the stock’s valuation. Astrana Health Earnings Report

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source